Teckro

Clinical Trial Protocol

Published by: Teckro
Downloads
Revenue

Description

Teckro transforms your clinical trial protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need, when they need it. Drugs from trials powered by Teckro have been granted priority review and approval by regulators in the US and Europe. Thousands of investigators and 20,000+ sites around the world rely on Teckro to execute clinical trials from biopharma sponsors, including 12 out of the Top 20 pharma companies. We support all therapeutic areas, all phases, and any trial model, whether traditional, virtual, or a hybrid approach - if Teckro isn't used on your clinical trial, ask your study manager for it.
Hide Show More...

Screenshots

Teckro FAQ

  • Is Teckro free?

    Yes, Teckro is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is Teckro legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does Teckro cost?

    Teckro is free.

  • What is Teckro revenue?

    To get estimated revenue of Teckro app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in Romania yet.
Ratings History

Teckro Reviews

No Reviews in Romania
App doesn't have any reviews in Romania yet.

Store Rankings

Ranking History
Category Rankings
Chart
Category
Rank
Top Free
255
Top Free
303
Top Free
308
Top Free
323
Top Free
415

Teckro Competitors

Name
RapidAI
iSchemaView
ESMO Events App
Preclarus
Investigator Site Portal
CTCAE plus
Beyond paper-based management
SITC Immunotherapy Guidelines
ESMO Interactive Guidelines
ASCO Guidelines
Medidata Rave RCM
Regulated Content Management
Signant Health IRT
Veeva Snap

Teckro Installs

Last 30 days

Teckro Revenue

Last 30 days

Teckro Revenue and Downloads

Gain valuable insights into Teckro performance with our analytics.
Sign up now to access downloads, revenue, and more.